U.S. Markets closed

Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks

Stock Research Monitor: FPRX, GNCA, and IMMU

LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on INCY sign up now at www.wallstequities.com/registration. WallStEquities.com observes the following stocks for today: Five Prime Therapeutics Inc. (NASDAQ: FPRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Immunomedics Inc. (NASDAQ: IMMU), and Incyte Corp. (NASDAQ: INCY). These companies are part of the Biotechnology industry, whichis a highly volatile and unpredictable sector due to the scientifically intensive operations of companies that reside in it. Markets served include medical, agricultural, environmental, and industrial. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Five Prime Therapeutics

Shares in South San Francisco, California headquartered Five Prime Therapeutics Inc. rose 1.02%, ending Tuesday's trading session at $16.87. The stock recorded a trading volume of 159,363 shares. The Company's shares are trading 3.35% below their 50-day moving average. Moreover, shares of the Company, which focuses on the discovery and development of immuno-oncology protein therapeutics, have a Relative Strength Index (RSI) of 49.65.

On June 28th, 2018, research firm Raymond James initiated a 'Market Perform' rating on the Company's stock. Get the full research report on FPRX for free by clicking below at:

www.wallstequities.com/registration/?symbol=FPRX

Genocea Biosciences

Cambridge, Massachusetts headquartered Genocea Biosciences Inc.'s stock declined slightly by 0.61%, closing the day at $0.83 with a total trading volume of 103,602 shares. The stock is trading 10.14% below their 50-day moving average. Shares of the Company, which discovers and develops novel cancer vaccines, have an RSI of 38.31. Access the free research report on GNCA now by signing up at:

www.wallstequities.com/registration/?symbol=GNCA

Immunomedics

On Tuesday, shares in Morris Plains, New Jersey headquartered Immunomedics Inc. recorded a trading volume of 2.33 million shares. The stock ended the day 1.51% higher at $24.81. The Company's shares have advanced 2.69% in the past month, 62.37% in the previous three months, and 204.23% over the past year. The stock is trading above its 50-day and 200-day moving averages by 11.98% and 53.31%, respectively. Furthermore, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases, have an RSI of 62.13.

On June 15th, 2018, Immunomedics (IMMU) announced the closing of its previously announced underwritten public offering of 11,500,000 shares of the Company's common stock at a public offering price of $24.00 per share. The total net proceeds from the offering for IMMU are estimated to be approximately $260 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. Are you already registered with Wall St. Equities? Do so now for free, and get the report on IMMU at:

www.wallstequities.com/registration/?symbol=IMMU

Incyte

Wilmington, Delaware headquartered Incyte Corp.'s stock dropped 2.01%, finishing yesterday's session at $70.18 with a total trading volume of 1.33 million shares. The Company's shares have advanced 0.24% in the last month and 3.02% in the previous three months. The stock is trading above its 50-day moving average by 3.58%. Additionally, shares of Incyte, which focuses on the discovery, development, and commercialization of proprietary therapeutics in the US, have an RSI of 52.90.

On June 21st, 2018, Incyte announced positive topline results from its ongoing pivotal Phase-2 REACH1 trial evaluating ruxolitinib (Jakafi®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute graft-versus-host disease. The study met its primary endpoint, demonstrating an overall response rate of 55% (n=39/71) at Day 28. In addition, the best overall response rate, the number of patients achieving a response at any time point during the study, was 73% (n=52/71).

On June 26th, 2018, research firm RBC Capital Markets downgraded the Company's stock rating from 'Outperform' to 'Sector Perform'. Aspiring Member, please take a moment to register below for your free research report on INCY at:

www.wallstequities.com/registration/?symbol=INCY

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities